Chapman MJ, Redfern JS, McGovern ME, Giral P (2010) Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther 126:314–345

Article  CAS  PubMed  Google Scholar 

Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT investigators (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149–1158

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207

Article  Google Scholar 

Abe M, Ozaki Y, Takahashi H, Ishii M, Masunaga N, Ismail TF, Iimuro S, Fujita R, Iwata H, Sakuma I, Nakagawa Y, Hibi K, Hiro T, Fukumoto Y, Hokimoto S, Miyauchi K, Ogawa H, Daida H, Shimokawa H, Saito Y, Matsuzaki M, Akao M, Kimura T, Nagai R (2021) Relation of renal function to mid-term prognosis of stable angina patients with high- or low-dose pitavastatin treatment: REAL-CAD substudy. Am Heart J 240:89–100

Article  CAS  PubMed  Google Scholar 

Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM, ASTEROID Investigators (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295:1556–1565

Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN, REVERSAL Investigators (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291:1071–1080

Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M, COSMOS Investigators (2009) Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J 73:2110–2117

Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M, JAPAN-ACS Investigators (2009) Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 54:293–302

Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y, MEGA Study Group (2006) Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368:1155–1163

Article  Google Scholar 

Scandinavian Simvastatin Survival Study Group (1994) The Scandinavian Simvastatin Survival Study (4S) (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383–1389

Google Scholar 

Mitsutake R, Niimura H, Miura S, Zhang B, Iwata A, Nishikawa H, Kawamura A, Kumagai K, Shirai K, Matsunaga A, Saku K (2006) Clinical significance of the coronary calcification score by multidetector row computed tomography for the evaluation of coronary stenosis in Japanese patients. Circ J 70:1122–1127

Article  PubMed  Google Scholar 

Tsukihashi Y, Shiga Y, Suematsu Y, Idemoto Y, Tashiro K, Yano Y, Kato Y, Kuwano T, Sugihara M, Miura S (2021) Presence and severity of coronary artery disease in patients who achieved intensive blood pressure reduction at the time of coronary computed tomography angiography. Hypertens Res 44:206–214

Article  CAS  PubMed  Google Scholar 

Inoue H, Shiga Y, Norimatsu K, Tashiro K, Futami M, Suematsu Y, Sugihara M, Nishikawa H, Katsuda Y, Miura S (2021) Associations between high-density lipoprotein functionality and major adverse cardiovascular events in patients who have undergone coronary computed tomography angiography. J Clin Med 10:2431

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kawahira Y, Shiga Y, Inoue H, Suematsu Y, Tashiro K, Kato Y, Fujimi K, Takamiya Y, Kuwano T, Sugihara M, Miura S (2021) Association between high-density lipoprotein cholesterol levels and major adverse cardiovascular events in patients who underwent coronary computed tomography angiography: FU-CCTA registry. Heart Vessels 36:1457–1465

Article  PubMed  Google Scholar 

Inoue H, Shiga Y, Tashiro K, Kawahira Y, Suematsu Y, Idemoto Y, Tano K, Kuwano T, Sugihara M, Nishikawa H, Katsuda Y, Miura S (2021) Association between the level of low-density lipoprotein cholesterol and coronary atherosclerosis in patients who have undergone coronary computed tomography angiography. Cardiol Res 12:10–15

Article  PubMed  Google Scholar 

Tashiro K, Inoue H, Shiga Y, Tsukihashi Y, Imaizumi T, Norimatsu K, Idemoto Y, Kuwano T, Sugihara M, Nishikawa H, Katsuda Y, Miura S (2020) Associations between high levels of high-density lipoprotein cholesterol and the presence and severity of corona artery disease in patients who have undergone coronary computed tomography angiography. J Clin Med Res 12:734–739

Article  CAS  PubMed  PubMed Central  Google Scholar 

Norimatsu K, Kuwano T, Miura S, Shimizu T, Shiga Y, Suematsu Y, Miyase Y, Adachi S, Nakamura A, Imaizumi S, Iwata A, Nishikawa H, Uehara Y, Saku K (2017) Significance of the percentage of cholesterol efflux capacity and total cholesterol efflux capacity in patients with orwithout coronary artery disease. Heart Vessels 32:30–38

Article  PubMed  Google Scholar 

Shiga Y, Miura S, Mitsutake R, Kawamura A, Uehara Y, Saku K (2010) Significance of serum high-density lipoprotein cholesterol levels for diagnosis of coronary stenosis as determined byMDCT in patients with suspected coronary artery disease. J Atheroscler Thromb 17:870–878

Article  CAS  PubMed  Google Scholar 

Mitsutake R, Miura S, Zhang B, Saku K (2010) HDL-associated factors provide additional prognostic information for coronary artery disease as determined by muldetector row computed tomography. Int J Cardiol 143:72–78

Article  PubMed  Google Scholar 

Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R (1990) Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15:827–832

Article  CAS  PubMed  Google Scholar 

Gensini GG (1983) A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 51:606

Article  CAS  PubMed  Google Scholar 

Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Borén J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A, European Atherosclerosis Society Consensus Panel (2013) Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 34:3478–3490. Erratum in: Eur Heart J 2020;41:4517

NDB open data (2021) https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000177182.html accessed date 8th Nov. 2023

Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW, STELLAR Study Group (2003) Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 92:152–160

Article  Google Scholar 

Staffa JA, Chang J, Green L (2002) Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346:539–540

Article  PubMed  Google Scholar 

Tremblay AJ, Lamarche B, Lemelin V, Hoos L, Benjannet S, Seidah NG, Davis HR Jr, Couture P (2011) Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men. J Lipid Res 52:558–565

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713–1722

Karalis DG (2023) Strategies of improving adherence to lipid-lowering therapy in patients with atherosclerotic cardiovascular disease. Curr Opin Lipidol 34:252–258

Article  CAS  PubMed  Google Scholar 

Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S, Ohmura H, Shoji T, Yokote K, Yoshida H, Yoshida M, Deguchi J, Dobashi K, Fujiyoshi A, Hamaguchi H, Hara M, Harada-Shiba M, Hirata T, Iida M, Ikeda Y, Ishibashi S, Kanda H, Kihara S, Kitagawa K, Kodama S, Koseki M, Maezawa Y, Masuda D, Miida T, Miyamoto Y, Nishimura R, Node K, Noguchi M, Ohishi M, Saito I, Sawada S, Sone H, Takemoto M, Wakatsuki A, Yanai H (2003) Japan atherosclerosis society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2022. J Atheroscler Thromb. https://doi.org/10.5551/jat.GL2022

Article  Google Scholar